文献速递心境障碍

KCNQ钾通道调节对抑郁伴快感缺失个体腹侧被盖区活动及连接的影响

Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia.
PubMed 文献 · Mol Psychiatry · 2025-03-25

研究将伴快感缺失的重性抑郁障碍患者随机分配至KCNQ通道开放剂依佐加滨(最高900 mg/日)或安慰剂治疗5周,在基线和治疗结束时进行金钱预期任务功能磁共振及静息态扫描;结果显示依佐加滨较安慰剂降低腹侧被盖区预期激活及中皮层功能连接,与临床前发现的腹侧被盖区过度活跃机制一致。

要点

  • 伴快感缺失的抑郁患者随机接受依佐加滨(最高900 mg/日)或安慰剂治疗5周。
  • 预期任务中腹侧被盖区激活存在显著药物×时间交互(F(1,34)=4.36,p=0.044),依佐加滨较安慰剂降低该激活。
  • 中皮层功能连接在基线高于健康对照,且依佐加滨较安慰剂降低该连接(F(1,33)=4.317,p=0.046)。

核心结论

  • 该转化研究结果与临床前发现一致,即抑郁中存在腹侧被盖区过度活跃,并提示KCNQ通道开放剂在伴抑郁和快感缺失个体中使该过度活跃正常化的作用机制。

研究设计与样本

  • 将伴快感缺失的重性抑郁障碍个体随机分配至为期五周的KCNQ通道开放剂依佐加滨(最高900 mg/日)或安慰剂。
  • 参与者在基线和治疗结束时完成金钱预期任务功能磁共振及静息态扫描。
  • 临床结果此前已报告;本研究检查基线及治疗结束时金钱预期中的腹侧被盖区活动,以及腹侧被盖区与腹内侧前额叶皮层(中皮层通路)和腹侧纹状体(中边缘通路)的静息态功能连接。

主要发现

  • 预期期间腹侧被盖区激活存在显著药物×时间交互(F(1,34)=4.36,p=0.044),依佐加滨组腹侧被盖区激活从治疗前到治疗后降低,相较安慰剂组。
  • 抑郁参与者在基线的中皮层功能连接高于健康对照组(t(56)=2.68,p=0.01),并与基线任务态功能磁共振中腹侧被盖区过度活跃相关(R=0.352,p=0.033)。
  • 中皮层连接从治疗前到治疗后降低,依佐加滨组相较安慰剂组(显著药物×时间交互,F(1,33)=4.317,p=0.046)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Up to half of individuals with depression do not respond to first-line treatments, possibly due to a lack of treatment interventions informed by neurobiology. A novel therapeutic approach for depression has recently emerged from translational work targeting aberrant activity of ventral tegmental area (VTA) dopamine neurons via modulation of the KCNQ voltage-gated potassium channels. In this study, individuals with major depressive disorder (MDD) with elevated anhedonia were randomized to five weeks of the KCNQ channel opener, ezogabine (up to 900 mg/day) or placebo. Participants completed functional MRI during a monetary anticipation task and resting-state at baseline and at end-of-treatment. The clinical results were reported previously. Here, we examined VTA activity during monetary anticipation and resting-state functional connectivity between the VTA and the ventromedial prefrontal cortex (mesocortical pathway) and ventral striatum (mesolimbic pathway) at baseline and end-of-treatment. Results indicated a significant drug-by-time interaction in VTA activation during anticipation (F(1,34) = 4.36, p = 0.044), where VTA activation was reduced from pre-to-post ezogabine, compared to placebo. Mesocortical functional connectivity was also higher in depressed participants at baseline compared to a healthy control group (t(56) = 2.68, p = 0.01) and associated with VTA hyper-activity during task-based functional MRI at baseline (R = 0.352, p = 0.033). Mesocortical connectivity was also reduced from pre-to-post ezogabine, compared to placebo (significant drug-by-time interaction, F(1,33) = 4.317, p = 0.046). Together this translational work is consistent with preclinical findings highlighting VTA hyper-activity in depression, and suggesting a mechanism of action for KCNQ channel openers in normalizing this hyper-activity in individuals with both depression and anhedonia.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Morris LS, Costi S, Hameed S, et al. Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia. Mol Psychiatry. 2025. PMID: 40133425. doi:10.1038/s41380-025-02957-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。